Get the Stockscreener App
11.10
4.82%
0.51
After Hours:
10.50
-0.60
-5.41%
Liquidia Corp stock is traded at $11.10, with a volume of 2.60M.
It is up +4.82% in the last 24 hours and up +9.68% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$10.59
Open:
$10.59
24h Volume:
2.60M
Relative Volume:
3.01
Market Cap:
$939.47M
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-14.42
EPS:
-0.77
Net Cash Flow:
$-52.85M
1W Performance:
+1.65%
1M Performance:
+9.68%
6M Performance:
-9.61%
1Y Performance:
+3.74%
1-Day Range:
$10.51
$11.22
1-Week Range:
$10.37
$11.44
52-Week Range:
$8.26
$16.99
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
11.10 | 939.47M | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Wells Fargo & Company Initiates Coverage on Liquidia (NASDAQ:LQDA) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $833,000 Stake in Liquidia Co. (NASDAQ:LQDA) - Defense World
Liquidia Co. (NASDAQ:LQDA) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $24.00 - MarketBeat
Liquidia stock gains after win in patent dispute with United Therapeutics - Seeking Alpha
Here’s Arquitos Capital Management’s Updates on Liquidia (LQDA) - Yahoo Finance
Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Has $187,000 Stake in Liquidia Co. (NASDAQ:LQDA) - Defense World
BNP Paribas Financial Markets Raises Stock Position in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Anson Funds Management LP Invests $1.76 Million in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia (NASDAQ:LQDA) Shares Down 4.2%Should You Sell? - MarketBeat
Whitefort Capital Management LP Has $17.02 Million Stake in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Judge Signals Doubt on Liquidia's FDA Drug Exclusivity Fight - Bloomberg Law
Cinctive Capital Management LP Takes $444,000 Position in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia CFO and COO Michael Kaseta sells shares worth $12,557 By Investing.com - Investing.com Nigeria
Liquidia Corp general counsel Russell Schundler sells $12,235 in stock - Investing.com India
Liquidia's chief business officer sells $5,237 in stock By Investing.com - Investing.com Canada
Liquidia's chief commercial officer sells $6,284 in stock By Investing.com - Investing.com Canada
Liquidia's chief commercial officer sells $6,284 in stock - Investing.com India
Liquidia CFO and COO Michael Kaseta sells shares worth $12,557 - Investing.com
Liquidia's chief business officer sells $5,237 in stock - Investing.com
HighVista Strategies LLC Buys 59,193 Shares of Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Caligan Partners LP Sells 2,242,353 Shares of Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Vestal Point Capital LP Reduces Holdings in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Acuta Capital Partners LLC Acquires Shares of 73,500 Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High? - Yahoo Finance
Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
FY2024 EPS Estimates for Liquidia Boosted by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Liquidia Raised by Lifesci Capital - MarketBeat
Liquidia Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Liquidia Corporation: Resilience In Face Of Formidable Opposition Can Pay Off (LQDA) - Seeking Alpha
Liquidia (NASDAQ:LQDA) Receives Buy Rating from Needham & Company LLC - MarketBeat
The Analyst Landscape: 11 Takes On Liquidia - Benzinga
Liquidia Corporation (NASDAQ:LQDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Q3 2024 Liquidia Corp Earnings Call Transcript - GuruFocus.com
Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory Challenges - GuruFocus.com
Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... - Yahoo Finance
Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... By GuruFocus - Investing.com Canada
Liquidia Technologies earnings beat by $0.07, revenue topped estimates - Investing.com
Liquidia Corp Q3 2024 Earnings: Revenue Hits $4.4M, EPS at $(0.3 - GuruFocus.com
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Uncovering Potential: Liquidia's Earnings Preview - Benzinga
Liquidia to Present at the Stifel 2024 Healthcare Conference - Yahoo Finance
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Liquidia Corporation Trade Ideas — NASDAQ:LQDA - TradingView
Earnings To Watch: Liquidia Corp (LQDA) Reports Q3 2024 Result - GuruFocus.com
Investors in Liquidia (NASDAQ:LQDA) have seen stellar returns of 186% over the past five years - Yahoo Finance
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024 - Yahoo Finance
Liquidia (LQDA) to Release Quarterly Earnings on Monday - MarketBeat
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 - Yahoo Finance
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kaseta Michael | CFO and COO |
Dec 02 '24 |
Sale |
11.51 |
1,091 |
12,557 |
312,328 |
| Schundler Russell | General Counsel |
Dec 02 '24 |
Sale |
11.51 |
1,063 |
12,235 |
487,328 |
| Adair Jason | Chief Business Officer |
Dec 02 '24 |
Sale |
11.51 |
455 |
5,237 |
119,223 |
| Saggar Rajeev | Chief Medical Officer |
Oct 18 '24 |
Sale |
11.19 |
2,526 |
28,266 |
204,857 |
| Schundler Russell | General Counsel |
Oct 14 '24 |
Sale |
11.11 |
2,576 |
28,613 |
486,048 |
| Saggar Rajeev | Chief Medical Officer |
Oct 14 '24 |
Sale |
11.11 |
2,260 |
25,103 |
207,383 |
| Moomaw Scott | Chief Commercial Officer |
Oct 14 '24 |
Sale |
11.11 |
1,527 |
16,961 |
152,798 |
| Kaseta Michael | CFO and COO |
Oct 14 '24 |
Sale |
11.11 |
3,892 |
43,231 |
311,076 |
| JEFFS ROGER | Chief Executive Officer |
Oct 14 '24 |
Sale |
11.11 |
8,053 |
89,450 |
812,193 |
| Adair Jason | Chief Business Officer |
Oct 14 '24 |
Sale |
11.11 |
1,146 |
12,729 |
118,574 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):